A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Immunomodulatory bispecific antibodies The human brain, with its billions of neurons and intricate networks, remains one of biology’s greatest mysteries. Neuroscience research r ...

AbTherx and Single Cell Technology ... but limited extracellular domain access, difficulty producing stable, functional antigens, and the lack of antibody technologies to access deep pockets ...

Allen Guo, CEO "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody," said Allen Guo, CEO.

Using this platform, Aprile and colleagues successfully generated single-domain antibodies (nanobodies) targeting intrinsically disordered proteins, or proteins that are not defined by one ...

Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell engagers, ...

Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell ...